Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016:2016:1602083.
doi: 10.1155/2016/1602083. Epub 2015 Dec 6.

Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

Peng Yun  1 , Ai-ming Du  2 , Xue-jun Chen  2 , Jing-cheng Liu  3 , Hu Xiao  3
Affiliations
Randomized Controlled Trial

Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

Peng Yun et al. J Diabetes Res. 2016.

Abstract

Objective: To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT).

Methodology: 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day, n = 67) or control group (no acarbose, n = 68). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed.

Results: During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%, P < 0.05); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm, P < 0.05).

Conclusions: Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.

PubMed Disclaimer

References

    1. Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. International Journal of Cardiology. 2006;107(1):11–20. doi: 10.1016/j.ijcard.2005.02.033. - DOI - PubMed
    1. Chiasson J.-L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension inpatients with impaired glucose tolerance: the STOP-NIDDM trial. Journal of the American Medical Association. 2003;290(4):486–494. doi: 10.1001/jama.290.4.486. - DOI - PubMed
    1. Tahrani A. A., Geen J., Hanna F. W. F., et al. Predicting dysglycaemia in patients under investigation for acute coronary syndrome. QJM. 2011;104(3):231–236. doi: 10.1093/qjmed/hcq184. - DOI - PubMed
    1. Wright R. S., Anderson J. L., Adams C. D., et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (Updating the 2007 Guideline): a report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2011;123(18):2022–2060. doi: 10.1161/cir.0b013e31820f2f3e. - DOI - PubMed
    1. Standl E., Schnell O. Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation. Diabetes and Vascular Disease Research. 2012;9(3):163–169. doi: 10.1177/1479164112441524. - DOI - PubMed

Publication types

LinkOut - more resources